Posters

OMNI TM in open-angle glaucoma treatment: a 24-month follow-up

Poster Details

First Author: I.Grabska-Liberek POLAND

Co Author(s):    P. Duda   M. Rogowska   J. Majszyk-Ionescu   A. Skowyra   I. Kane        

Abstract Details

Purpose:

To analyse the safety and efficacy of OMNI TM procedure in reducing intraocular pressure (IOP) and number of glaucoma drugs in eyes with open-angle glaucoma (OAG).

Setting:

OMNI TM is a new surgical procedure for OAG treatment and the first non-implantable minimally-invasive glaucoma surgery. It uses a single, self-sealing clear corneal incision with 360-degree viscodilation of Schlemm’s canal, followed by transluminal trabeculotomy, performed via gonioscopic guidance.

Methods:

A single-surgeon prospective clinical study. 17 eyes in mild or moderate stage of 15 OAG adult patients taking maximum 3 glaucoma medications underwent OMNI TM surgery. 9 eyes underwent OMNITM alone and 8 eyes underwent OMNITM combined with cataract surgery. Changes in intraocular pressure (IOP) and postoperative complications will be examined. Success is defined as post-operative IOP reduction ≥ 20% without glaucoma medication ("complete success") or with topical treatment ("qualified success"). The number of medications before and after surgery will be considered.

Results:

2 males and 13 females with a mean age of 71.06 years. IOP decreased from a mean of 20.41±4.32 mmHg preoperatively to 13.44±4.70, 13.76±2.97, 13.43±2.95, 13.71±2.58, 12.64±1.98, 12.40±3.24 and 12.86±1.86 mmHg at 1 week, 1 month, 3 months, 6 months, 1 year, 18 months and 2 years (in eyes which achieve checkpoint). The number of anti-glaucoma medications dropped from a mean of 2.59 to 0.06, 0.18, 0.29, 0.43, 0.64, 1.10 and 1.14 at checkpoints. Complications were limited to IOP-spikes (six eyes), hyphema (six eyes) and fibrin in the anterior chamber (three cases) that resolved within first week after surgery.

Conclusions:

The OMNI TM is a promising approach for the treatment of non-advanced OAG. The procedure achieves reduction of the IOP and number of glaucoma medications. It also demonstrates good safety profile. The main advantages of the procedure are: short surgical learning curve, fast to perform, implant free and sutureless, can be combined with cataract surgery, sparing of the conjunctiva and sclera of incisions. Further studies are needed.

Financial Disclosure:

is employed by a for-profit company with an interest in the subject of the presentation, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented